Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Status:
Unknown status
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out.
Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control
group (PC+ placebo). The efficacy was evaluated every six weeks.Follow-up continued until
disease progression or death.